Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

847.86 +6.91 (+0.82%)

Streaming Delayed Price Updated: 10:15 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

August 06, 2024

Via Benzinga

The Analyst Verdict: argenx In The Eyes Of 27 Experts ↗

July 29, 2024

Via Benzinga

Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday ↗

July 29, 2024

Via Benzinga

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

July 25, 2024

From argenx SE

Via GlobeNewswire

Breaking Down argenx: 12 Analysts Share Their Views ↗

May 10, 2024

Via Benzinga

The Analyst Verdict: argenx In The Eyes Of 12 Experts ↗

April 18, 2024

Via Benzinga

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024

From argenx SE

Via GlobeNewswire

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

July 16, 2024

From argenx SE

Via GlobeNewswire

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

July 16, 2024

From Zai Lab Limited

Via Business Wire

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

June 25, 2024

From argenx SE

Via GlobeNewswire

Why Is European Drugmaker Argenx Stock Trading Higher On Monday? ↗

June 24, 2024

The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.

Via Benzinga

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval ↗

June 24, 2024

This is the second approval for the biotech company's drug, Vyvgart Hytrulo.

Via Investor's Business Daily

Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 24, 2024

Via Benzinga

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

June 21, 2024

From argenx SE

Via GlobeNewswire

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

June 17, 2024

From argenx SE

Via GlobeNewswire

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 04, 2024

From argenx SE

Via GlobeNewswire

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗

May 30, 2024

Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.

Via Investor's Business Daily

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗

May 29, 2024

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Via Benzinga

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump ↗

May 29, 2024

The company says it's still running additional testing of the drug, calling the results "positive."

Via Investor's Business Daily

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 09, 2024

Via Benzinga

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

May 09, 2024

Via Benzinga

ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From argenx SE

Via GlobeNewswire

argenx announces results of Annual General Meeting of Shareholders

May 07, 2024

From argenx SE

Via GlobeNewswire

argenx to Present at BofA Securities 2024 Health Care Conference

May 07, 2024

From argenx SE

Via GlobeNewswire

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

May 02, 2024

From argenx SE

Via GlobeNewswire

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

April 16, 2024

From argenx SE

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.